|
Originally published In Press as doi:10.1074/jbc.M702679200 on April 2, 2007
J. Biol. Chem., Vol. 282, Issue 20, 15081-15089, May 18, 2007
NFATc3 Mediates Chronic Hypoxia-induced Pulmonary Arterial Remodeling with -Actin Up-regulation*
Sergio de Frutos,
Rhyannon Spangler,
Dominique Alò, and
Laura V. González Bosc1
From the
Department of Cell Biology and Physiology, School of Medicine, University of New Mexico, Albuquerque, New Mexico 87131
Physiological responses to chronic hypoxia include polycythemia, pulmonary arterial remodeling, and vasoconstriction. Chronic hypoxia causes pulmonary arterial hypertension leading to right ventricular hypertrophy and heart failure. During pulmonary hypertension, pulmonary arteries exhibit increased expression of smooth muscle- -actin and -myosin heavy chain. NFATc3 (nuclear factor of activated T cells isoform c3), which is aCa2+-dependent transcription factor, has been recently linked to smooth muscle phenotypic maintenance through the regulation of the expression of -actin. The aim of this study was to determine if: (a) NFATc3 is expressed in murine pulmonary arteries, (b) hypoxia induces NFAT activation, (c) NFATc3 mediates the up-regulation of -actin during chronic hypoxia, and (d) NFATc3 is involved in chronic hypoxia-induced pulmonary vascular remodeling. NFATc3 transcript and protein were found in pulmonary arteries. NFAT-luciferase reporter mice were exposed to normoxia (630 torr) or hypoxia (380 torr) for 2, 7, or 21 days. Exposure to hypoxia elicited a significant increase in luciferase activity and pulmonary arterial smooth muscle nuclear NFATc3 localization, demonstrating NFAT activation. Hypoxia induced up-regulation of -actin and was prevented by the calcineurin/NFAT inhibitor, cyclosporin A (25 mg/kg/day s.c.). In addition, NFATc3 knock-out mice did not showed increased -actin levels and arterial wall thickness after hypoxia. These results strongly suggest that NFATc3 plays a role in the chronic hypoxia-induced vascular changes that underlie pulmonary hypertension.
Received for publication, March 28, 2007
* This work was supported in part by Dedicated Health Research Funds of the UNM SOM and a Postdoctoral Fellowship from Ministerio de Educación y Ciencia, Spain (to S. D. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: Dept. of Cell Biology and Physiology, School of Medicine, University of New Mexico, MSC 08 4750, Albuquerque, NM 87131. Tel.: 505-272-0605; Fax: 505-272-9105; E-mail: lgonzalezbosc{at}salud.unm.edu.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. de Frutos, L. Duling, D. Alo, T. Berry, O. Jackson-Weaver, M. Walker, N. Kanagy, and L. Gonzalez Bosc
NFATc3 is required for intermittent hypoxia-induced hypertension
Am J Physiol Heart Circ Physiol,
May 1, 2008;
294(5):
H2382 - H2390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Hamidi, S. Prabhakar, and S. I. Said
Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion
Eur. Respir. J.,
January 1, 2008;
31(1):
135 - 139.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|